Biogen released its Q2 FY20 financial results, reporting a 7% decrease in biosimilar revenues compared to FY19.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Jul 22, 2020
Biogen released its Q2 FY20 financial results, reporting a 7% decrease in biosimilar revenues compared to FY19.
By Bioblast Editor | Jul 22, 2020
Cadila Pharma announces it has launched Bevaro® (biosimilar bevacizumab) in India. Bevaro® s indicated for ovarian cancer, glioblastoma, colorectal cancer, breast cancer, lung cancer, cervical cancer and kidney cancer.
By Bioblast Editor | Jul 22, 2020
Genentech publishes the results from its Ph III Archway study, evaluating its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD). Genentech reported that 98.4% of patients were able to go six months without ...
By Bioblast Editor | Jul 21, 2020
Novartis releases its Q2 FY20 financial results, reporting COVID-19 negatively impacted demand for Lucentis® (ranibizumab).
By Naomi Pearce | Jul 20, 2020
Significant biosimilar activities this week include
09 Jul 20 | AU | The Australian Generic and Biosimilar Medicines Association (GBMA) announced it reached over 540,000 Australians in its Biosimilar Awareness Week, which was held digitally May 25-29.
14 Jul 20 ...
By Bioblast Editor | Jul 20, 2020
AstraZeneca announced interim results from ongoing Ph I/II trial showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
By Bioblast Editor | Jul 20, 2020
Spherix reports that the EU market for AbbVie’s Humira® has been negatively impacted by gastroenterologists increasingly prescribing alternative mechanism of action agents, including Stelara® (ustekinumab) and Entyvio® (vedolizumab) for ulcerative colitis (UC) and Cro...
By Bioblast Editor | Jul 17, 2020
VentureTECH, Duopharma and PanGen Biotech announce a joint venture to develop a Malaysian biosimilar production facility.
By Bioblast Editor | Jul 17, 2020
Bio-Thera Solutions annnounces a licensing agreement with Pharmapark for BAT2506 (biosimilar golimumab candidate). Under the agreement, Pharmapark will have exclusive rights to distribute and market the drug in Russia and other CIS countries.
By Bioblast Editor | Jul 17, 2020
In an interview with Generics update, Sandoz Canada announces it is aiming for 10 biosimilar launches in the next decade, with pegfilgrastim and rituximab to be launched shortly.
SUBSCRIBE TO PEARCE IP